Our proprietary technology utilizes supercritical fluids, which allow for prolonged therapeutic drug dosing after polymer absorption.
Read more...Our products are designed to make clinically meaningful improvements in patient outcomes, and are available in select countries around the world.
Read more...Our ongoing clinical trials are designed to confirm the effectiveness of our technology in interventional cardiology.
Read more...Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience
Click to see full press releaseSee an interview with Prof. R. J. de Winter, M.D., Ph.D. following his late-breaking trial presentation at EuroPCR 2017
Watch video ...EuroPCR 2017 Panelists: P. W. Serruys, E. Edelman, R.J. de Winter, K. Milewski, and G. Sardella
Watch video . . .